Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Sensipar | Cinacalcet hydrochloride | Secondary hyper-parathyroidism in chronic kidney disease | Do not list | Complete | ||
Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Active | |||
Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
Omnaris | Ciclesonide nasal spray | Allergic Rhinitis (seasonal and perennial) | Do not list | Complete | ||
Alvesco | Ciclesonide | asthma | List | Complete | ||
Ledaga | chlormethine hydrochloride | T-cell lymphoma | Do not reimburse | Complete | ||
Erbitux | Cetuximab | Cancelled | ||||
Erbitux | Cetuximab | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
Cimzia | certolizumab pegol | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
Cimzia | Certolizumab pegol | Ankylosing spondylitis | List with criteria/condition | Complete |